Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Infection risk related to gastrointestinal endoscopic procedures during the SARS-CoV-2 pandemic].
Fábián A, Bor R, Tóth T, Bacsur P, Bálint A, Farkas K, Milassin Á, Molnár T, Resál T, Rutka M, Gelley A, Gyökeres T, Hagymási K, Kovalcsik Z, Kristóf T, Lombay B, Lovik K, Miheller P, Rácz I, Salló Z, Tomcsik Z, Varga M, Vincze Á, Szepes Z. Fábián A, et al. Among authors: kristof t. Orv Hetil. 2022 Nov 13;163(46):1814-1822. doi: 10.1556/650.2022.32633. Print 2022 Nov 13. Orv Hetil. 2022. PMID: 36373579 Hungarian.
[Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].
Lakatos L, Czeglédi Z, Dávid G, Kispál Z, Kiss LS, Palatka K, Kristóf T, Molnár T, Salamon A, Demeter P, Miheller P, Szamosi T, Banai J, Papp M, Bene L, Kovács A, Rácz I, Lakatos PL. Lakatos L, et al. Among authors: kristof t. Orv Hetil. 2010 Feb 14;151(7):250-8. doi: 10.1556/OH.2010.28805. Orv Hetil. 2010. PMID: 20133244 Hungarian.
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztonyi B, Golovics PA, Kristóf T, Lakatos L, Csontos ÁA, Juhász M, Nagy F, Palatka K, Papp M, Patai Á, Lakner L, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Szalay B, Molnár T, Lakatos PL. Gecse KB, et al. Among authors: kristof t. J Crohns Colitis. 2016 Feb;10(2):133-40. doi: 10.1093/ecco-jcc/jjv220. Epub 2015 Dec 10. J Crohns Colitis. 2016. PMID: 26661272 Clinical Trial.
Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL. Gonczi L, et al. Among authors: kristof t. J Crohns Colitis. 2017 Jun 1;11(6):697-705. doi: 10.1093/ecco-jcc/jjw203. J Crohns Colitis. 2017. PMID: 27838610
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
Bálint A, Rutka M, Végh Z, Kürti Z, Gecse KB, Banai J, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Patai Á, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Bor R, Milassin Á, Fábián A, Nagy F, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Lakatos PL, Molnár T, Farkas K. Bálint A, et al. Among authors: kristof t. Expert Opin Drug Saf. 2017 Aug;16(8):885-890. doi: 10.1080/14740338.2017.1323330. Epub 2017 May 26. Expert Opin Drug Saf. 2017. PMID: 28504555 Free article.
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, Golovics PA, Lovasz BD, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Patai A, Salamon A, Szamosi T, Szepes Z, Toth GT, Vincze A, Szalay B, Molnar T, Lakatos PL. Gonczi L, et al. Among authors: kristof t. Inflamm Bowel Dis. 2017 Nov;23(11):1908-1915. doi: 10.1097/MIB.0000000000001237. Inflamm Bowel Dis. 2017. PMID: 28922253
A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése.
Miheller P, Kristóf T, Bor R, Farkas K, Golovics P, Harsányi L, Müller KE, Milassin Á, Palatka K, Schäfer E, Szamosi T, Sarlós P, Molnár T. Miheller P, et al. Among authors: kristof t. Orv Hetil. 2024 Mar 12;165(Supplement-1):37-64. doi: 10.1556/650.2024.33050. Print 2024 Mar 12. Orv Hetil. 2024. PMID: 38470491 Hungarian. No abstract available.
Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.
Lakatos PL, Czegledi Z, David G, Kispal Z, Kiss LS, Palatka K, Kristof T, Nagy F, Salamon A, Demeter P, Miheller P, Szamosi T, Banai J, Papp M, Bene L, Kovacs A, Racz I, Lakatos L. Lakatos PL, et al. Among authors: kristof t. J Crohns Colitis. 2010 Sep;4(3):283-90. doi: 10.1016/j.crohns.2009.11.011. J Crohns Colitis. 2010. PMID: 21122517
40 results